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ABSTRACT
The global Tuberculosis epidemic (TB) poses a significant public health threat. While the 
consequences of TB treatment interruption are indisputable, the knowledge about the timing 
and prognostic factors of TB treatment interruption is fundamental. Despite a considerable 
amount of evaluation, the timing and prognostic factors of TB treatment interruption have 
been inconsistently identified from one study to another. Therefore, this study aimed to 
examine the evidence obtained from published literature on the timing and prognostic 
factors of TB treatment interruption at different points of the treatment course. In this review, 
three databases namely Pubmed, Scopus, and Science Direct were used to identify articles 
published from January 2003 to February 2018. This was based on the inclusion criteria and 
keywords including ‘default’, ‘survival time’, ‘tuberculosis’, and ‘treatment interruption’. 
The nine selected studies were prospective and retrospective cohort studies conducted in 
developing countries. The diversity of the study’s participants and TB treatment interruption 
definition were allowed, thus delineating a 
heterogeneous finding. This review suggests 
that the interruption predominantly occurred 
during the maintenance phase of treatment 
course. Despite the finding, a considerable 
gap in understanding the prognostic factors 
at different time points of TB treatment 
interruption was elicited. The heterogeneity 
across the studies may limit the inferences 
and warrant further evaluation. In essence, 
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the time-related information should be integrated into framing impactful public health 
strategy, while a vigorous attempt on the evaluation of the cognitive, behavioural and 
psychosocial aspects may be beneficial.
Keywords: Default, survival time, treatment interruption, tuberculosis 
INTRODUCTION 
The 20th century has demonstrated a significant public health threat posed by the re-
emergence of an ancient airborne disease which is Tuberculosis (TB). The TB mortality has 
been substantial, reaching approximate 1.6 million in 2016, while the slow falling rate of TB 
incidence has been illustrated across the nations (World Health Organization, 2017). This 
has called for an intensified global effort to end TB global epidemic via End TB strategy. 
As one of the major obstacles in successfully treating 85% of the detected TB cases, TB 
treatment interruption should be the focus area of improvement in TB management (World 
Health Organization, 2017). 
TB treatment interruption is defined as a history of stopping treatment for two or 
more consecutive months (World Health Organization, 2014). Evidently, TB treatment 
interruption has led to devastating consequences including delayed sputum conversion, 
drug resistance, longer treatment regimes, incomplete treatment, hence collectively exhibit 
prolonged infectiousness to the community (Dominguez-Castellano et al., 2003; Kuaban 
et al., 2009; Marx et al., 2012; Nahid et al., 2011; Pablos-Méndez et al. 1996; Vree et al., 
2007). Importantly, TB treatment interruption has also posed significant economic burden 
and dependency through increased hospital admission and bed occupancy, thus leading to 
significant psychosocial impact (Cerdá et al., 2014; Pettit et al., 2013).  
The recent two decades have demonstrated vigorous efforts to combat TB treatment 
interruption. In parallel with the defaulter tracing system, Directly Observed Treatment, 
Short-course (DOTS) has been a global core strategy to increase treatment adherence 
since 1993 (Maher, 2009; World Health Organization, 2017). On top of fee exemption 
for the anti-TB drug in most developing countries, fixed-dose combination tablets for 
tuberculosis treatment have been advocated since the 1980s, primarily to ensure optimal 
adherence (World Health Organization, 1999). Notwithstanding the established policy 
and legislative framework intended to optimise acceptance and access to treatment, TB 
treatment interruption remains a global public health challenge across nations particularly 
in high disease burden countries (Sabate, 2003; World Health Organization, 2017). In 
developing and high TB burden countries, TB treatment interruption has been reported 
ranging from 6 to 30% (Connolly et al., 1999; Dodor, 2004; Kliiman & Altraja, 2010).
Previous studies delineated risk factors of TB treatment interruption. These include 
younger age, male, low educational level, unemployment, being immigrant and HIV 
infection, which had significantly influenced TB treatment default (Chee et al., 2000; 
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Connolly et al., 1999; da Silva Garrido et al., 2012; Kliiman & Altraja, 2010; Millet et 
al., 2009; Naing et al., 2001; Tachfouti et al., 2013). Meanwhile, smoking and alcoholism 
have been consistently reported as the risk factors of TB treatment interruption (Bagchi et 
al., 2010; Chandrasekaran et al., 2005; Kliiman & Altraja, 2010; Sulaiman, & Ali, 2010; 
Vijay et al., 2010). 
In the recent years, the outstandingly high burden due to TB treatment interruption has 
resulted in major awareness about the importance of assessing the timing of interruptions 
and determinants of the interruptions at different stages of the treatment course (Kruk et 
al., 2008).  While much has been elicited on the determinants of TB treatment interruption, 
to the best of our knowledge there has been a scarce systematic review on the timing of 
interruption and prognostic factors contributing to different timing of treatment interruption. 
In addition, there are a number of prognostic factors reported previously, but few had been 
consistently identified from one study to another (Jenkins et al., 2013; Jepchumba et al., 
2017; Akessa et al., 2015). Therefore, this review aims to examine evidence from published 
literature on the timing of TB treatment interruption in TB treatment, and subsequently 
to assess prognostic factors of TB treatment interruption at different time points of the 
treatment course. The duration information from survival analysis is fundamental to assist 
in designing time relevant intervention strategies in TB case holding and management, 
at which a different timeline of impactful adherence strategy can be planned accordingly.
METHODS
Data Sources and Literature Search Strategy 
Literature search was systematically conducted via three electronic databases, namely 
PubMed, Scopus, and ScienceDirect in February 2018. The Pubmed search terms were 
(“survival”[MeSHTerms] OR (“survival”[All Fields] OR “survival time”[MeSHTerms]) 
OR (“survival time”[AllFields]) OR (“time*”[MesHTerms]) OR (“time*”[AllFields]) 
AND (“tuberculosis”[MeSHTerms] OR “tuberculosis”[AllFields]) AND (“treatment 
interruption”[MeSHTerms] OR “treatment interruption”[AllFields] OR (“treatment 
default”[MeSHTerms]OR “treatment default”[AllFields] OR (“default”[MeSHTerms]OR 
“default”[AllFields]). A similar search strategy was adapted in order to search for articles 
from ScienceDirect, and Scopus. The search for scholarly literature was also extended to 
Google Scholar. 
All retrieved abstracts and titles were read and screened by three independent 
investigators (Q.S, S.M.S, and L.P.Y). The inclusion criteria were; original studies in 
English language, cohort studies of patients with tuberculosis, studies with TB treatment 
interruption reported as the primary outcome, as well as papers presenting any temporal 
data on TB treatment interruption such as mean/median time to default, survival probability, 
cumulative hazard or hazard function. In terms of TB treatment interruption, a variety of 
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criteria for defining interruption was accepted (for example early treatment interruption, or 
interruption of two or more months). Due to the scarcity of relevant articles, the date range 
was expanded to include published articles in peer-reviewed journals from February 2003 to 
February 2018, instead of limiting the search only to the past 10 years. The types of papers 
excluded from the analysis were reviews or editorials, non-peer-reviewed review literature 
such as technical reports and web-based guidelines, articles focusing on unfavourable 
outcomes rather than TB treatment interruption, as well as articles describing temporal 
data without the assessment of prognostic factors. Full text of potentially eligible articles 
were retrieved and screened for eligibility, through which the discrepancies between the 
reviewers’ preferences on potentially eligible articles were resolved.  
Search Outcome
The search was electronically conducted according to the Preferred Reporting Items for 
Systematic reviews and Meta-Analyses (PRISMA) guidelines, 2009 (Moher et al., 2009). 
The PRISMA flow diagram for study selection is described in Figure 1. Firstly, 267 articles 
Figure 1. PRISMA flowchart for systematic search on timing and prognostic factors of TB treatment 
interruption
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were identified from three databases. After excluding duplicated articles, assessment of 
titles and abstracts was executed, through which unrelated articles were omitted from 
further screening. After screening and looking for eligible articles based on the inclusion 
criteria, only 20 articles were examined. A sum of 11 articles were excluded due to the 
following reasons; articles focusing on unfavourable outcomes rather than TB treatment 
interruption or articles focusing on the survival time of treatment interruption without 
emphasizing prognostic factors.
Quality Assessment, Data Extraction and Data Analysis 
The title, abstract and full text of every article retrieved from the search were screened by 
one reviewer (Q.S). To ensure rigour, a second set of reviewers (S.M.S and L.P.Y) were 
employed to assess the retrieved study for any doubt on the article’s eligibility. The related 
articles were reviewed based on characteristics of the individual study including study 
details, exposure assessment, operational definition of treatment interruption, statistical 
method, as well as study outcomes including treatment interruption rate, survival time, 
survival probability and prognostic factors of TB treatment interruption. The included 
articles were evaluated for its risk of bias using Quality in Prognosis Studies (QUIPS) 
tool (Hayden et al., 2008). Assessment of bias was conducted based on six domains 
including the study’s participants, study’s attrition, prognostic factor measurement, outcome 
measurement, study confounding as well as statistical analysis and reporting. Some studies 
showed the lack of descriptions for prognostic factor measurement and study confounding 
particularly on the definition of prognostic factors, unclear methods for imputation of 
missing prognostic factors, as well as unclear description and measurement of important 
confounders. The list of studies is summarized in Table 1. Despite an overt criticism on the 
studies’ quality and generalizability, it was not intended for article exclusion.  Meanwhile, a 
meta-analysis of comparable studies was not conducted due to the presence of heterogeneity 
across the studies. Hence, a qualitative synthesis was performed.
RESULT 
Finally, nine (9) eligible study articles were found to have met the predetermined study 
objectives and inclusion criteria. These articles were qualitatively synthesized, and the 
results were presented as follows. 
Characteristic of Prognostic Studies 
To date, several studies had been conducted to examine the time of TB treatment interruption 
and its prognostic factors. Most of the studies were designed as prospective cohort studies, 
and the majority of assessments were conducted in high TB burden countries. There had 
been a variation in the number of participants ranging from 249 to 90170 of patients 
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seeking treatments from both hospitals and health clinics. Most of the participants were 
from the middle-age group.  In term of exposure assessment, there had been prominent 
diversity across the studies. Most of the studies evaluated the demography of the patients, 
organizational factors as well as biomedical assessments such as comorbidities and 
treatment-related factors, but a limited assessment was made in cognitive, behavioural and 
psychosocial aspects. The characteristics of the individual study are described in Table 2. 
With the exemption of two studies conducted by Hill et al. (2005) and Masini et al. 
(2016), most of the studies had computed Cox Proportional Hazard in analysing time to 
event data. Due to violated proportionality assumption for the Cox regression, Hill et al. 
(2005) computed the Extended Cox Regression in his assessment. Meanwhile, Masini et al. 
(2016) incorporated both fixed effects and accounted for the geographic region of Kenya 
via a random effect’s component, hence mixed effect Cox proportional hazard modelling 
was computed. 
TB Treatment Interruption  
The burden of TB treatment interruption for the individual study is summarized in Table 
3. In general, the proportion of TB treatment interruption ranged from 5.0 to 25.2%. The 
three highest treatment interruption burdens were recorded according to assessments 
across high TB burden countries (Hill et al., 2005; Pefura-Yone et al., 2014; Shargie & 
Lindtj, 2007). In addition, there was considerable variation in term of the definition of TB 
treatment interruption used in the studies. Instead of defining TB treatment interruption 
as two consecutive months of interruption, Rutherford et al. (2013) and Hill et al. (2005) 
used different operational definitions of interruption which were two consecutive weeks 
and three consecutive days of interruption respectively.
Survival Time, Survival Probability or Cumulative Hazard of TB Treatment 
Interruption
In this review, median survival time refers to length of time from either the date of diagnosis 
or treatment initiation, after which 50% of the TB patients are still in the treatment course, 
or have yet to develop TB treatment interruption (Kleinbaum, 1996). Meanwhile, survival 
probabilities or survival function is the probability that the individual survives from the 
date of diagnosis or treatment initiation, until the last day of treatment. To date, the median 
survival time and survival probability had been differently reported across the study 
locations, as presented in Table 3. Most of the studies revealed that the median time of TB 
treatment interruption was depicted during the maintenance phase of TB treatment (Akessa 
et al., 2015; Hill et al., 2005; Jenkins et al., 2013; Pefura-Yone et al., 2014). As opposed to 
the preceding findings, a prospective cohort study involving 264 of newly diagnosed PTB 
smear-positive patients in Bandung, Indonesia revealed that the median time to treatment 
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interruption was 36 days (IQR=7–99) (Rutherford et al., 2013). Consistently, Masini et al. 
(2016) via a large retrospective cohort study involving 91099 TB patients in Kenya, had 
elicited evidence that the hazard rate of TB treatment interruption was highest during the 
intensive phase. Incongruent with preceding findings, Jepchumba et al. (2017) and Sylvère 
(2015) during their respective assessments at Kenya and West Africa, revealed that the 
median time of TB treatment interruption was towards the completion of the intensive phase.
Prognostic Factors In Terms of Time for TB Treatment Interruption 
Prognostic factors in terms of time for TB treatment interruption elicited from the prognostic 
studies are presented in Table 3. These factors can be conveniently divided into socio-
demographic and high-risk behaviours, clinical factors, health service factors as well as 
behavioural and cognitive factors. 
Socio-demographic Factors and High-Risk Behaviour. In consistent with findings of 
Shargie and Lindtj (2007), and Sylvere (2015) demonstrated the prospective association 
between age and different time points of TB treatment interruption even though both had 
contradicting findings.  Meanwhile, several other studies demonstrated that the age factor is 
an important confounder to be addressed during TB treatment interruption. Similarly, gender 
has also exerted confounding effect in most of the studies. Despite extensive evaluation 
of the demographic and socioeconomic profiling in most of the studies, there has been 
inconsistent findings across residential area, educational level, and family income. In the 
lens of high-risk behaviours, there is a limited evaluation of the smoking status, illegal 
drug use as well as alcohol consumption. 
Clinical Characteristics. In this review, clinical parameters such as underlying disease, 
treatment-related factors, and comorbidity information were widely studied particularly in 
retrospective cohort studies. In essence, there have been consistent influences demonstrated 
by the type of TB patients and HIV infection on the time of TB treatment interruption, in 
which those with previous history of TB treatment and HIV positive status show higher 
probability of defaulting (Jenkins et al., 2013; Masini et al., 2016; Sylvere, 2015). In 
addition, there have been inconsistent findings in term of the history of hospitalization, 
body weight, symptoms improvement, sputum culture, chest x-ray grading as well as 
comorbidities. 
Cognitive and Behavioural Factors. Despite limited assessment of cognitive and 
behavioural factors influence on the time of TB treatment interruption, Hill et al. (2005) 
evidently demonstrated that among 301 PTB patients in Gambia, those who were uncertain 
about the effectiveness of the standard treatment were 3.64 times at risk of developing 
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treatment interruption as compared to the reference group. However, this effect varied 
across the time, in which perceived benefits was the only exerting and significant effect on 
the time of TB treatment interruption in the first 90 days of the treatment course, but not 
thereafter. On the other hand, Rutherford et al. (2013) attempted a temporal assessment 
of TB knowledge and perceived stigma, but there were no significant influences to TB 
treatment interruption observed in terms of TB treatment interruption.
Health Service Factors. Health service factors such as staff adequacy, perceived access 
to healthcare centre and perceived patients’ satisfaction have gained much interest from 
researchers during the assessment of the time of TB treatment interruption. It was evident in 
three distinct studies that health service access was found to have a significant association 
with different times of treatment interruption (Hill et al., 2005; Rutherford et al., 2013; 
Shargie & Lindtj, 2007).  Earlier, Hill et al. (2005) in a prospective cohort study involving 
301 TB patients in an urban community in Gambia, reported that patients with a travel time 
of more than half an hour or spent more than six dalasis (0.16 euro) for travel access had a 
higher risk of default, which was significantly observed after three months of treatment. In 
this study, the author postulated the correlation of built-up cost over time with a higher rate 
of defaulting during the maintenance phase. In contrast, a temporal assessment among 249 
TB patients in Indonesia showed that travel time, travel distance (in kilometres) and travel 
cost did not influence TB treatment interruption significantly (Rutherford et al. (2013). 
Instead, patients who walked to the treatment centre had a higher risk of early treatment 
interruption, as the median time of default was 36 days.  In the meantime, Shargie and Lindtj 
(2007) depicted that walking time of more than two hours posed a risk of maintenance 
phase treatment interruption in the rural community of Southern Ethiopia. The two latter 
studies shared a similarity, as both evaluated rural communities who predominantly walked 
to the treatment centres. 
DISCUSSION 
In this review, most of the studies shared several common characteristics, in which the 
selected studies were conducted in developing and high TB burden countries, and mean age 
of recruited participants was within the middle age group. However, quantitative analysis 
could not be performed due to limited finalized studies and considerable diversity across the 
studies, particularly on the study designs, duration of follow-up, as well as the operational 
definition of TB treatment interruption. Two studies did not explicitly report on the timing 
of default. Instead, the cumulative hazard risk or hazard functions were presented (Marsini 
et al., 2016; Shargie & Lindtj, 2007). 
Notwithstanding the foregoing restriction, this review revealed that the timing of 
treatment interruption predominantly occurred during the maintenance phase. This finding 
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is incongruent with a previous systematic review conducted across the temporal data 
from developing countries which also demonstrated the maintenance phase as the point 
of exit from the treatment course (Kruk et al., 2008). In addition, this has been supported 
by previous qualitative studies whereby it was highlighted that most of the patients had 
significant symptoms improvement by the time they were in the maintenance phase 
(Martins et al., 2008; Widjanarko et al., 2009). Having said that, Rutherford et al. (2013) 
demonstrated that the median time of the TB treatment interruption was 36 days (IQR=7-
99), whilst Masini et al. (2016) pointed out that the hazard rate of TB treatment interruption 
was highest during intensive phase, which collectively raised a postulation that additional 
effort for case holding relies on rigorous policy implementation and effectiveness of the 
existing programme in individual country to ensure adherence. 
In the context of prognostic factors of TB treatment interruption, various factors 
contributing to TB treatment interruption at different time points have been identified. These 
factors are framed via socio-demographic and high-risk behaviour, clinical characteristics, 
health service factors as well as cognitive and behavioural factors. Prominently, travel 
distance and HIV infection were demonstrated as one of the prognostic factors of time 
to TB treatment interruption (Hill et al., 2005; Jenkins et al., 2013; Masini et al., 2016; 
Rutherford et al., 2013; Shargie & Lindtj, 2007; Sylvere, 2015).  Undoubtedly, there are 
inconsistent findings, which largely influenced by study settings and study participants. 
Several studies included those with comorbidities such as HIV infection, liver disease, and 
diabetes which were predisposed to the complexity of treatment responses and standard 
care, thus influenced the mean time of duration of follow up.  The comorbidities factors 
could also contribute to the competing risk of event occurrence, whereby this would lead 
to overestimation of the hazard of other factors. 
 Above all, findings from this review should be interpreted with caution. Firstly, this 
review was confined to published studies in which the generalizability of study population 
may render some restrictions. Crucially, the large heterogeneity was observed across the 
published studies particularly on study design, study participants and study population, 
duration of follow up, sample size and operational definition of TB treatment interruption. 
For example, there was considerable variation of TB treatment interruption rate, which 
strongly depending on the duration of follow up to allow sufficient event to be encountered, 
as well as the diversity of baseline characteristics of recruited participants. Therefore, a 
meta-analysis could not be performed to estimate the aggregate effect measure. In addition, 
this review included two studies dated more than 10 years. In this light, existing national 
programs and treatment protocol may have evolved and advances thereby impaired 
comparability of the studies. 
Fundamentally, this review sheds light on the gap of individual research on longitudinal 
assessment of TB treatment interruption. It was demonstrated that most researchers focus 
Qudsiah Suliman, Salmiah Md. Said and Lim Poh Ying
1522 Pertanika J. Sci. & Technol. 27 (4): 1509 - 1525 (2019)
on demographic and biomedical context influences. While behavioural and psychosocial 
contexts have been echoed by WHO as a crucial aspect to be explored in TB treatment 
interruption, the prospective assessment of TB treatment interruption at different time 
points of the treatment course should emphasize on high risk behaviour, cognitive and 
behavioural aspect as well as psychosocial context which has been widely demonstrated in 
the literature as the determinants of TB treatment interruption (Sabate, 2003; World Health 
Organization, 1999). In addition, the assessment of events during the course of treatment, 
such as drug side effects and care provider-patient interactions, which could considerably 
influence a patient’s decision to continue treatment, was not demonstrated in this review. 
This gap finding should be further explored, hence to endeavour a holistic assessment 
of health services factors which could influence TB treatment interruption. In terms of 
analysis, the quality of statistical reporting in future prognostic studies can be enhanced 
by subgroup analysis and by allowing a competing risks analysis of the hazard estimation 
in catering for diverse participants and organizational characteristics. 
CONCLUSION 
Although this review generally reveals that TB treatment interruption occurs more frequently 
during the maintenance phase, there has been a concomitant gap in understanding the 
prognostic factors of different time points of TB treatment interruption. The heterogeneity 
across the studies particularly on study design and operational definition of TB treatment 
interruption may limit solid inferences on the outcome measure, which requires further 
evaluation. In essence, health practitioners should integrate time-related information, while 
furthering suggestion that prognostic studies should incorporate assessments of cognitive, 
behavioural studies and psychosocial evaluation. The findings would be able to provide 
further evidence in framing future public health strategy. 
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